Download PDF
Arzneimittelforschung 2008; 58(2): 86-90
DOI: 10.1055/s-0031-1296473
Sex Hormones and Inhibitors
Editio Cantor Verlag Aulendorf (Germany)

Anti-Tumor-Promoting Activity of Tibolone and its Metabolites

Diego Colombo
1   Dipartimento di Chimica, Biochimica e Biotecnologie per la Medicina, Università, di Milano, Milan, Italy
,
Patrizia Ferraboschi
1   Dipartimento di Chimica, Biochimica e Biotecnologie per la Medicina, Università, di Milano, Milan, Italy
,
Laura Franchini
1   Dipartimento di Chimica, Biochimica e Biotecnologie per la Medicina, Università, di Milano, Milan, Italy
,
Hoyoku Nishino
2   Department of Molecular Biochemistry, Kyoto Prefectural University of Medicine, Kyoto, Japan
,
Jyunko Takayasu
2   Department of Molecular Biochemistry, Kyoto Prefectural University of Medicine, Kyoto, Japan
,
Harukuni Tokuda
2   Department of Molecular Biochemistry, Kyoto Prefectural University of Medicine, Kyoto, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

The aim of this study was to evaluate the cancer chemopreventive potential of the widely prescribed drug tibolone (17α-ethynyl-7α-methyl-5(10)-estren-3-one, CAS 5630-53-5) and its main metabolites, 17α-ethynyl-7α-methyl-4-estren-3-one (CAS 1162-60-3), 17α-ethynyl-7α-methyl-5(10)-estrene-3α,17β-diol (CAS 100239-44-9) and 17α-ethynyl-7α-methyl-5(10)-estrene-3β,17β-diol (CAS 100239-45-0), by studying their anti-tumor-promoting activity. To this aim the test compounds were submitted to the short term in vitro assay for the inhibition of Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) as a primary screening for anti-tumor promoters. All the compounds showed high inhibitory activity and low cytotoxicity as compared to literature data. To extend the study to an animal model, tibolone and its 3α-hydroxy metabolite (CAS 100239-44-9) were also assayed in the in vivo two-stage on mouse skin carcinogenesis test, exhibiting significant inhibitory effects on TPA promoted mouse skin papillomas formation. A comparison with literature data indicated them as more potent compounds than other steroids previously studied such as digitoxigenin, cortisone, hydrocortisone, and prednisolone.

Key words

Anti-tumor-promoting compounds - CAS 5630-53-5 - Epstein-Barr virus - Progestins - Steroids - Tibolone, cancer chemoprevention, metabolites
 

  • Literature

  • 1 Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002; 87: 16-23
    CrossrefPubMedGoogle Scholar
  • 2 Sandker GW, Vos RME, Delbressine LPC, Slooff MJH, Meijer DKF, Groothuis GMM. Metabolism of 3 pharmacologically active-drugs in isolated human and rat hepatocytes– Analysis of interspecies variability and comparison with metabolism in-vivo . Xenobiotica. 1994; 24: 143-155
    CrossrefPubMedGoogle Scholar
  • 3 Murakami A, Ohigashi H, Koshimizu K. Chemoprevention: insights into biological mechanisms and promising food factors. Food Rev Int. 1999; 15: 335-395 and references therein
    CrossrefPubMedGoogle Scholar
  • 4 Konoshima T, Takasaki M, Anti-tumor-promoting activities (cancer chemopreventive activities) of natural products. In Attaur Rahman. ed Studies in natural products chemistry (bioactive natural products–Part E). Kyoto (Japan): Pharmaceutical University; 2000. p 215-267
    CrossrefGoogle Scholar
  • 5 Inada A, Nakanishi T, Konoshima T, Kozuka M, Tokuda H, Nishino H et al. Studies on inhibitors of skin tumor promotion. VII. Inhibitory effects of steroids on Epstein-Barr virus Activation. Shoyakugaku Zasshi. 1990; 44: 215-218
    PubMedGoogle Scholar
  • 6 Belman S, Troll W. The Inhibition of Croton Oil-promoted Mouse Skin Tumorigenesis by Steroid Hormones. Cancer Res. 1972; 32: 450-454
    PubMedGoogle Scholar
  • 7 Colombo D, Scala A, Taino IM, Toma L, Ronchetti F, Tokuda H et al. 1-O-, 2-O- and 3-O-β-Glycosyl-sn-glycerols: structure- antitumor-promoting activity relationship. Bioorg Med Chem Lett. 1996; 6: 1187-1190
    CrossrefPubMedGoogle Scholar
  • 8 Colombo D, Franchini L, Toma L, Ronchetti F, Nakabe N, Konoshima T et al. Anti-tumor-promoting activity of simple models of galactoglycerolipids with branched and un-saturated acyl chains. Eur J Med Chem. 2005; 40: 69-74 and references therein
    CrossrefPubMedGoogle Scholar
  • 9 De Jongh H P, van Vliet N P. U.S. patent 3340279, Organon 1967.
    PubMed
  • 10 Ferraboschi P, Colombo D, Reza-Elahi S. A pratical chemoenzymatic approach to the synthesis of 3-hydroxy metabolites of tibolone. Tetrahedron-Asymmetry. 2002; 13: 2583-2586
    PubMedGoogle Scholar
  • 11 Hoyte RM, Brown TJ, MacLusky NJ, Hochberg RB. 7-Alpha-methyl-17-alpha-(E-2’-[I-125]iodovinyl)-19-nortestosterone–A new radioligand for the detection of androgen receptor. Steroids. 1993; 58: 13-23
    CrossrefPubMedGoogle Scholar
  • 12 Tokuda H, Konoshima T, Kozuka M, Kimura T. Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate and telocidin B-induced Epstein-Barr virus by saponins and its related compounds. Cancer Lett. 1988; 40: 309-317
    CrossrefPubMedGoogle Scholar
  • 13 Shirahashi H, Murakami N, Watanabe M, Nagatsu A, Sakakibara J, Tokuda H et al. Glycolipids. VIII. Isolation and identification of antitumor-promoting principles from the fresh-water cyanobacterium Phormidium tenue. Chem Pharm Bull. 1993; 41: 1664-1666
    CrossrefPubMedGoogle Scholar
  • 14 Inada A, Nakanishi T, Konoshima T, Kozuka M, Tokuda H, Nishino H et al. Anti-Tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors. Biol Pharm Bull. 1993; 16: 930-931
    CrossrefPubMedGoogle Scholar
  • 15 Mayer LaP, Pearsall NA, Christian PJ, Devine PJ, Payne CM, McCuskey MK et al. Long-term effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide. Reprod Toxicol. 2002; 16: 775-781
    CrossrefPubMedGoogle Scholar
  • 16 Markievicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem. 1990; 35: 535-541
    CrossrefPubMedGoogle Scholar
  • 17 Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001; 76: 231-238
    CrossrefPubMedGoogle Scholar
  • 18 Schatz F, Kuczynski E, Kloosterbooer L, Krikun G, Buchwalder LF, Rahman M et al. Tibolone exerts progestional inhibition of matrix metalloproteinase expression in human endometrial stromal cells. Steroids. 2006; 71: 768-775
    CrossrefPubMedGoogle Scholar
  • 19 Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella JJ. Progestins and breast cancer. Steroid Biochem Molec Biol. 1998; 65: 225-235
    PubMedGoogle Scholar
  • 20 Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 2004; 1654: 123-143
    PubMedGoogle Scholar
  • 21 Van de Ven J, Donker GH, Sprong M, Blankenstein MA, Thijssen JHH. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol. 2002; 81: 237-247
    CrossrefPubMedGoogle Scholar
  • 22 Raobaikady B, Day JM, Purohit A, Potter BVL, Reed MJ. The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites. J Steroid Biochem Mol Biol. 2005; 94: 229-237
    CrossrefPubMedGoogle Scholar
  • 23 Kandouza M, Lombetb A, Perrotc JY, Jacob D, Carvajalb S, Kazemd A et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol. 1999; 69: 463-471
    CrossrefPubMedGoogle Scholar
  • 24 Vanhoecke BW, Bracke ME, Kloosterboer HJ, Depypere HT. Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro . Maturitas. 2006; 54: 229-237
    CrossrefPubMedGoogle Scholar
  • 25 Desreux J, Kloosterboer H, Noel A, Frankenne F, Lemaire M, Putman M et al. Effects of tibolone on sulfatase pathway of estrogens metabolism and on growth of mcf-7 human breast tumors implanted in ovariectomized nude mice. Gynecol Obstet Invest. 2007; 63: 31-38
    CrossrefPubMedGoogle Scholar
  • 26 Lippert C, Seeger H, Wallwiener D, Mueck AO. Tibolone versus 17β-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur J Gynaec Oncol. 2002; 23: 127-130
    PubMedGoogle Scholar
  • 27 Mueck AO, Lippert C, Seeger H, Wallwiener D. Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch Gynecol Obstet. 2003; 267: 139-144
    CrossrefPubMedGoogle Scholar
  • 28 DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther. 1992; 54: 63-128
    CrossrefPubMedGoogle Scholar
  • 29 Kapadia GJ, Azuine MA, Takayasu J, Konoshima T, Takasaki M, Nishino H et al. Inhibition of Epstein-Barr virus early antigen activation promoted by 12-O-tetradecanoylphor-bol-13-acetate by the non-steroidal anti-inflammatory drugs. Cancer Lett. 2000; 161: 221-229
    CrossrefPubMedGoogle Scholar